Function of phosphorylation of NF-kB p65 ser536 in prostate cancer oncogenesis
暂无分享,去创建一个
Michael Ittmann | Li Zhang | Chad J. Creighton | Yiqun Zhang | C. Creighton | M. Ittmann | Yiqun Zhang | Jianghuai Wang | Li Zhang | L. Xin | Longjiang Shao | Li Xin | Jianghua Wang | Long-jiang Shao
[1] C. Kleer,et al. Altered receptor trafficking in Huntingtin Interacting Protein 1-transformed cells. , 2003, Cancer cell.
[2] K. Pienta,et al. CCL2 Protects Prostate Cancer PC3 Cells from Autophagic Death via Phosphatidylinositol 3-Kinase/AKT-dependent Survivin Up-regulation* , 2008, Journal of Biological Chemistry.
[3] K. Pienta,et al. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. , 2009, Cancer research.
[4] O. Cussenot,et al. Recurrent cytogenetic alterations of prostate carcinoma and amplification of c‐myc or epidermal growth factor receptor in subclones of immortalized pnt1 human prostate epithelial cell line , 1995, International journal of cancer.
[5] J. Inoue,et al. NF‐κB activation in development and progression of cancer , 2007 .
[6] Pingfu Fu,et al. Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. , 2004, Neoplasia.
[7] I. Panagopoulos,et al. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer , 2006 .
[8] K. Pienta,et al. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. , 2010, Cytokine & growth factor reviews.
[9] Toby Lawrence,et al. IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation , 2005, Nature.
[10] R. Eeles,et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate , 2007, Oncogene.
[11] M. Ittmann,et al. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. , 2008, Cancer research.
[12] M. Schmitz,et al. Constitutive and interleukin-1-inducible phosphorylation of p65 NF-{kappa}B at serine 536 is mediated by multiple protein kinases including I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to , 2004, The Journal of biological chemistry.
[13] N. Colburn,et al. Suppression of p65 phosphorylation coincides with inhibition of IkappaBalpha polyubiquitination and degradation. , 2005, Molecular carcinogenesis.
[14] D. Longo,et al. Phosphorylation of RelA/p65 on Serine 536 Defines an IκBα-independent NF-κB Pathway* , 2005, Journal of Biological Chemistry.
[15] H. Pahl,et al. Activators and target genes of Rel/NF-kappaB transcription factors. , 1999, Oncogene.
[16] R. Matusik,et al. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. , 2008, Cancer research.
[17] P. Nelson,et al. A Three-Marker FISH Panel Detects More Genetic Aberrations of AR, PTEN and TMPRSS2/ERG in Castration-Resistant or Metastatic Prostate Cancers than in Primary Prostate Tumors , 2013, PloS one.
[18] R. Matusik,et al. NF-κB gene signature predicts prostate cancer progression. , 2014, Cancer research.
[19] D. Longo,et al. Phosphorylation of RelA/p65 on serine 536 defines an I{kappa}B{alpha}-independent NF-{kappa}B pathway. , 2005, The Journal of biological chemistry.
[20] Tien-Huang Lin,et al. CCL2 increases αvβ3 integrin expression and subsequently promotes prostate cancer migration. , 2013, Biochimica et biophysica acta.
[21] I. Mellinghoff,et al. Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[22] M. Merville,et al. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. , 2005, Trends in biochemical sciences.
[23] 湯智昕,et al. CCL2 increases alpha v bets3 integrin expression and subsequently promotes prostate cancer migration , 2013 .
[24] Y Pawitan,et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007, Oncogene.
[25] M. Ittmann,et al. FGF17 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasia , 2004, The Prostate.
[26] Hongyun Wang,et al. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. , 2013, The Journal of clinical investigation.
[27] S. Balk,et al. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. , 2009, Cancer research.
[28] G. Bartsch,et al. CCL2 promotes integrin-mediated adhesion of prostate cancer cells in vitro , 2015, World Journal of Urology.
[29] Michael Ittmann,et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. , 2006, Cancer research.
[30] S. Yadav,et al. Recent insights into NF‐κB signalling pathways and the link between inflammation and prostate cancer , 2014, BJU international.
[31] M. Ittmann,et al. The Fibroblast Growth Factor Receptor-4 Arg388 Allele Is Associated with Prostate Cancer Initiation and Progression , 2004, Clinical Cancer Research.
[32] J. Inoue,et al. NF-kappaB activation in development and progression of cancer. , 2007, Cancer science.
[33] R. Henrique,et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. , 2006, Neoplasia.
[34] Toby Lawrence,et al. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. , 2005, Nature.
[35] O. Witte,et al. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[36] Matthew J. Craig,et al. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. , 2007, Neoplasia.
[37] M. Merville,et al. Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation , 2005 .
[38] H. Pahl. Activators and target genes of Rel/NF-κB transcription factors , 1999, Oncogene.
[39] O. Ludkovski,et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome , 2008, Modern Pathology.
[40] N. Colburn,et al. Insufficient p65 phosphorylation at S536 specifically contributes to the lack of NF-kappaB activation and transformation in resistant JB6 cells. , 2004, Carcinogenesis.
[41] I. Panagopoulos,et al. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. , 2006, Genes, chromosomes & cancer.
[42] J. Moy,et al. Stimulus‐specific regulation of chemokine expression involves differential activation of the redox‐responsive transcription factors AP‐1 and NF‐κB , 1999, Journal of leukocyte biology.
[43] N. Colburn,et al. Suppression of p65 phosphorylation coincides with inhibition of IκBα polyubiquitination and degradation , 2005 .
[44] B. Bao,et al. Inactivation of AR / TMPRSS 2-ERG / Wnt Signaling Networks Attenuates the Aggressive Behavior of Prostate Cancer Cells , 2011 .
[45] N. Perkins. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway , 2006, Oncogene.
[46] M. Ittmann,et al. GGAP2/PIKE-a directly activates both the Akt and nuclear factor-kappaB pathways and promotes prostate cancer progression. , 2009, Cancer research.
[47] J. Tchinda,et al. Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.
[48] M. Ittmann,et al. The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling. , 2014, Endocrinology.
[49] Mazhar Adli,et al. IKK-i/IKKϵ Controls Constitutive, Cancer Cell-associated NF-κB Activity via Regulation of Ser-536 p65/RelA Phosphorylation* , 2006, Journal of Biological Chemistry.
[50] P. Möller,et al. NF-κB signaling in prostate cancer: A promising therapeutic target? , 2012, World Journal of Urology.
[51] Andrzej Kudlicki,et al. Modulation of Gene Expression Regulated by the Transcription Factor NF-κB/RelA* , 2014, The Journal of Biological Chemistry.
[52] W. V. Berghe,et al. Regulation of the transcriptional activity of the nuclear factor-κB p65 subunit , 2002 .
[53] J Cuzick,et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.
[54] Matthew J. Craig,et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. , 2007, Cancer research.
[55] E. Campo,et al. Activation of nuclear factor-κB in human prostate carcinogenesis and association to biochemical relapse , 2005, British Journal of Cancer.
[56] A. Sood,et al. Highly Specific Targeting of the TMPRSS2/ERG Fusion Gene Using Liposomal Nanovectors , 2012, Clinical Cancer Research.
[57] D. Berney,et al. Duplication of the fusion of TMPRSS 2 to ERG sequences identifies fatal human prostate cancer , 2009 .
[58] Adam S. Kibel,et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007 .
[59] B. Bao,et al. Inactivation of AR/TMPRSS2-ERG/Wnt Signaling Networks Attenuates the Aggressive Behavior of Prostate Cancer Cells , 2011, Cancer Prevention Research.
[60] E. Corey,et al. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone , 2008, Clinical & Experimental Metastasis.
[61] N. Palanisamy,et al. Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. , 2011, Cancer research.
[62] J. Squire. TMPRSS2-ERG and PTEN loss in prostate cancer , 2009, Nature Genetics.
[63] P. Kantoff,et al. Inherited Variants in the Chemokine CCL2 Gene and Prostate Cancer Aggressiveness in a Caucasian Cohort , 2010, Clinical Cancer Research.
[64] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[65] Patricia D. Castro,et al. Celastrol Suppresses Tumor Cell Growth through Targeting an AR-ERG-NF-κB Pathway in TMPRSS2/ERG Fusion Gene Expressing Prostate Cancer , 2013, PloS one.
[66] K. Pienta,et al. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. , 2006, Neoplasia.
[67] K. Pienta,et al. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. , 2010, Journal of the National Cancer Institute.
[68] Adrian V. Lee,et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] F. Rizzi,et al. Polyphenon E(R), a standardized green tea extract, induces endoplasmic reticulum stress, leading to death of immortalized PNT1a cells by anoikis and tumorigenic PC3 by necroptosis. , 2014, Carcinogenesis.
[70] D. Galson,et al. Monocyte chemotactic protein‐1 (MCP‐1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion , 2006, The Prostate.